Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > TRENDS
TRENDS
- Number of Females MRs Breaks 9,000 Mark with 1 in 3 in Their 20s, but Number in Management Positions Remains Low
September 19, 2014
- With Entry of SGLT-2 Inhibitors, Competition Heating Up Again in Oral Anti-Diabetes Drug Market
September 12, 2014
- Molecular-Targeted Treatments for Refractory Thyroid Cancer Debut, Giving Patients Hope
September 5, 2014
- Competition Likely to Heat Up in RA Biologics Market Although Growth Continues
August 29, 2014
- Smaller Drug Makers Actively Expanding Overseas Focus, Shedding Conventional Business Models
August 18, 2014
- Old Giving Way to New in Osteoporosis Market as Competition among New Drugs Launched Since 2010 Increases
August 8, 2014
- Development Activity in Pulmonary Hypertension Market Accelerates with Debut of Japan’s First CTEPH Treatment
July 23, 2014
- Will Blopress AG Launched Prior to Patent Expiration Dominate the Market?
July 11, 2014
- Entry of Lixiana Will Further Intensify Competition in Market for NOACs
July 4, 2014
- With Sales of Aricept, Pariet Plummeting, Eisai to Focus on Investment in FY2014 with an Eye to Growth Track in FY2015
June 27, 2014
- MTPC Predicts Remicade Biosimilar “Will Not Have a Major Impact”
June 20, 2014
- Novo Nordisk Launches Hemophilia A Treatment NovoEight; Will Compete Directly with Baxter’s Advate
June 13, 2014
- Different Stances on Biosimilars Setting Domestic Generic Houses Apart as “Post-Small Molecule” Era Approaches
June 6, 2014
- Risk Management Could Be Key to Success of Highly Anticipated New NSCLC Treatment Giotrif
May 30, 2014
- Cost-Reduction Becoming a Top Priority for Domestic Drug Makers Due to Sluggish Sales of Long-Listed Drugs, Impact of NHI Pricing System Reform
May 28, 2014
- Foreign Drug Makers Seeking to Offset Risk in US, European Markets by Driving Growth in “Attractive” Japanese Market
May 23, 2014
- With Growth in the Number of CMRs Slowing, Can JCSOA Reach Its Goal of “5,000 CMRs by the End of 2015”?
May 16, 2014
- Shionogi’s New Midterm Business Plan Aims for Realistic Growth Targets for Domestic Sales Focusing on “Strategic Products”
April 24, 2014
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…